Cargando…

Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis

PURPOSE: In the treatment of patients with high-risk neuroblastoma, different doses of (131)I-metaiodobenzylguanidine ((131)I-MIBG) are administered at different time points during treatment. Toxicity, mainly haematological (thrombocytopenia), from (131)I-MIBG therapy is known to occur in extensivel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bleeker, Gitta, Schoot, Reineke A., Caron, Huib N., de Kraker, Jan, Hoefnagel, Cees A., van Eck, Berthe L., Tytgat, Godelieve A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788185/ https://www.ncbi.nlm.nih.gov/pubmed/23921531 http://dx.doi.org/10.1007/s00259-013-2510-z

Ejemplares similares

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
por: Garaventa, A, et al.
Publicado: (1999)

123I‐MIBG scintigraphy and 18F‐FDG‐PET imaging for diagnosing neuroblastoma
por: Bleeker, Gitta, et al.
Publicado: (2015)

Impact of mediastinal, liver and lung (123)I-metaiodobenzylguanidine ((123)I-MIBG) washout on calculated (123)I-MIBG myocardial washout
por: Verberne, Hein J., et al.
Publicado: (2009)

Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)

MON-202 Germline SDHB Exon 1 Deletion Is Associated with Absence of (131)I-metaiodobenzylguanidine (MIBG) Uptake in Malignant Paragangliomas
por: Petenuci, Janaina, et al.
Publicado: (2020)

Upfront consolidation treatment with (131)I‐mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high‐risk neuroblastoma
por: Feng, Jianhua, et al.
Publicado: (2020)

I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma
por: Sato, Yuya, et al.
Publicado: (2012)

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
por: DuBois, S G, et al.
Publicado: (2015)

Sequelae and survivorship in patients treated with (131)I-MIBG therapy
por: Sze, W C C, et al.
Publicado: (2013)

The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.
por: Jodrell, D. I., et al.
Publicado: (1988)

Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours
por: Nwosu, A C, et al.
Publicado: (2008)

Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective
por: Kayano, Daiki, et al.
Publicado: (2015)

The Vital Role of (131) I-MIBG in Localization of Paraganglioma at Unusual Sites
por: Singhal, Tejasvini, et al.
Publicado: (2022)

I-131 mIBG Scintigraphy Curie Versus SIOPEN Scoring: Prognostic Value in Stage 4 Neuroblastoma
por: Riaz, Saima, et al.
Publicado: (2018)

The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: a meta-analysis
por: He, Huihui, et al.
Publicado: (2022)

Variations in (123)I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation
por: Verberne, Hein J., et al.
Publicado: (2007)

Designing and Comparing Performances of Image Processing Pipeline for Enhancement of I-131-metaiodobenzylguanidine Images
por: Pandey, Anil Kumar, et al.
Publicado: (2021)

Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy
por: Mastrangelo, S, et al.
Publicado: (2001)

Complete remission of metastatic pheochromocytoma in (123)I-metaiodobenzylguanidine scintigraphy after a single session of (131)I-metaiodobenzylguanidine therapy: a case report
por: Sugino, Teruaki, et al.
Publicado: (2017)

Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.
por: Vaidyanathan, G., et al.
Publicado: (1996)

Improved outcome of (131)I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma
por: Corroyer-Dulmont, Aurélien, et al.
Publicado: (2017)

(123)I metaiodobenzylguanidine (MIBG) uptake predicts early relapse of neuroblastoma using semi-quantitative SPECT/CT analysis
por: Kitamura, Yoshiyuki, et al.
Publicado: (2021)

Nothing but NET: A review of norepinephrine transporter expression and efficacy of (131)I-mIBG therapy
por: Streby, Keri A, et al.
Publicado: (2015)

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
por: Pryma, Daniel A., et al.
Publicado: (2019)

Positive (68)Ga-DOTANOC PET/CT with negative (131)I- metaiodobenzylguanidine scan in a case of Glomus Jugulare
por: Damle, Nishikant A., et al.
Publicado: (2013)

Clinical performance and radiation dosimetry of no-carrier-added vs carrier-added (123)I-metaiodobenzylguanidine (MIBG) for the assessment of cardiac sympathetic nerve activity
por: Verberne, Hein J., et al.
Publicado: (2008)

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis
por: Bleeker, Gitta, et al.
Publicado: (2014)

Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG
por: Ezziddin, Samer, et al.
Publicado: (2012)

Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review
por: Pitton Rissardo, Jamir, et al.
Publicado: (2023)

131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
por: Gaze, M. N., et al.
Publicado: (1992)

Iodine-131MIBG SPECT/CT in neuroendocrine tumours: An institutional experience
por: Verma, Priyanka, et al.
Publicado: (2012)

Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2013)

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021)

Metastatic Pheochromocytoma Diagnosed with (131) I-MIBG SPECT/CT Imaging in a Patient with Pathogenic VHL Mutation
por: Vankadari, Kousik, et al.
Publicado: (2022)

(131)I–Tositumomab in lymphoma
por: Cheung, M.C., et al.
Publicado: (2009)

False Positive Radioiodinated Metaiodobenzylguanidine ((123)I-MIBG) Uptake in Undifferentiated Adrenal Malignant Tumor
por: Jung, Hee Soo, et al.
Publicado: (2015)

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors
por: Bushnell, David L, et al.
Publicado: (2014)

Unusual Presentation of Bladder Paraganglioma: Comparison of (131)I MIBG SPECT/CT and (68)Ga DOTANOC PET/CT
por: Jain, Tarun Kumar, et al.
Publicado: (2016)

(68)Ga-DOTATATE PET/CT Compared with (131)I-MIBG SPECT/CT in the Evaluation of Neural Crest Tumors
por: Shahrokhi, Pezhman, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9g2n03igq18phfgliu69h6bmbk